SCHEMBL4065715

SCHEMBL4065715

Fc1ccc(C=Cc2ncnc3[nH]ccc23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 4/20 0.51
TTBK1 Q5TCY1 3/20 0.46
TTBK2 Q6IQ55 3/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
IP6K1 Q92551 1/20 0.43
IP6K3 Q96PC2 1/20 0.43
MAPK14 Q16539 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
JAK2 O60674 2/20 0.40
JAK3 P52333 3/20 0.39
AURKA O14965 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065710 1.00 TRPA1 (0.51) TRPA1TTBK1TTBK2MKNK1MKNK2
SCHEMBL4070983 0.85 TTBK1 (0.52) TTBK1TTBK2KDM4EALDH1A1GLA
SCHEMBL4070985 0.85 TTBK1 (0.52) TTBK1TTBK2KDM4EALDH1A1GLA
SCHEMBL4067270 0.84 JAK2 (0.53) TRPA1TTBK1TTBK2MAPK14KDM4E
SCHEMBL4067267 0.84 JAK2 (0.53) TRPA1TTBK1TTBK2MAPK14KDM4E
SCHEMBL4067159 0.84 TTBK1 (0.49) TTBK1TTBK2JAK2JAK3AKT2
SCHEMBL4067155 0.84 TTBK1 (0.49) TTBK1TTBK2JAK2JAK3AKT2
SCHEMBL6660882 0.76 IP6K1 (0.46) MKNK1IP6K1IP6K3KDM4EMEN1
SCHEMBL857800 0.76 TRPA1 (0.44) TRPA1IP6K1IP6K3MAPK14KDM4E
SCHEMBL6660879 0.76 IP6K1 (0.46) MKNK1IP6K1IP6K3KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140171454-A1 Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-19 US disclosed
US-8633205-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
EP-1844050-B1 PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMA (US) 2009-01-14 EP disclosed
EP-1844050-A1 PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE Vertex Pharmaceuticals, Inc. (US) 2007-10-17 EP disclosed
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED 2007-01-04 US disclosed
WO-2006096270-A1 PYRROLOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-09-14 WO disclosed
US-20060183761-A1 Pyrrolopyrimidines useful as inhibitors of protein kinase LEDEBOER MARK 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004762-A9 Pyrrolopyrimidines useful as inhibitors of protein kinase PRKDC, MAP3K20, MAP3K5 TRPA1 4366/4885TTBK1 328/4885TTBK2 297/4885
US-20140171454-A1 Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases PRKDC, DCK, CDK2 TRPA1 4123/4885TTBK1 376/4885TTBK2 276/4885
US-20060183761-A1 Pyrrolopyrimidines useful as inhibitors of protein kinase PRKDC, MAP3K20, MAP3K5 TRPA1 4366/4885TTBK1 328/4885TTBK2 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.